The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer.

The pCR rate in the HR non-deficient patients was 20% without Cb and 40.7% with Cb, but did not reach statistical significance (P=0.146). 41 Pooled analysis of six phase II clinical trials (including GeparSixto), in which patients with TNBC received a platinum agent, demonstrated that patients with high HRD score were significantly more likely to achieve a pCR than those with HR-nondeficient tumors: 53% vs 18% (adjusted od

also in 111,027 other papers

44 , 45 This maybe the reason behind the fact that improvement in pCR by 20% in the case of the Neo-ALLTO trial, narrowly missed statistical significance in the ALLTO trial (HR 0.84, 97.5 % CI 0.70-1.02). 46 , 47 Selected ongoing Cb NACT studies in TNBC There are several studies evaluating various schedules and combinations of Cb in the NACT of TNBC ( Table 2 ).

also in 227 other papers